AMGN : Summary for Amgen Inc. - Yahoo Finance

U.S. Markets closed

Amgen Inc. (AMGN)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
165.74-0.30 (-0.18%)
At close: 4:00PM EDT
People also watch
BIIBGILDCELGMRKBMY
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close166.04
Open166.69
Bid165.00 x 1000
Ask165.94 x 100
Day's Range165.08 - 166.93
52 Week Range133.64 - 184.21
Volume2,521,587
Avg. Volume3,966,655
Market Cap122.06B
Beta1.76
PE Ratio (TTM)16.19
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield4.60 (2.78%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Why You're Smart to Buy Jazz Pharmaceuticals plc
    Motley Foolyesterday

    Why You're Smart to Buy Jazz Pharmaceuticals plc

    More good news could be on the way soon for Jazz Pharmaceuticals.

  • American City Business Journalsyesterday

    Google life sciences spinoff soaks up huge space (video)

    There can be a flipside to biotech industry success: When a company wins regulatory approval for a potentially top-selling drug, it becomes a buyout target — and the consequences for the local real estate market can be unexpected. Take Onyx Pharmaceuticals. Kyprolis, the South San Francisco company’s treatment for the blood cancer known as multiple myeloma, won the attention of Amgen Inc., which bought Onyx in 2013 for $10 billion.

  • Amgen's (AMGN) Humira Biosimilar Receives Approval in EU
    Zacks2 days ago

    Amgen's (AMGN) Humira Biosimilar Receives Approval in EU

    Amgen, Inc. (AMGN) announced that its biosimilar version of AbbVie Inc.'s (ABBV) rheumatoid arthritis (RA) drug Humira has been approved by the European Commission (EC).